News

Video

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

Author(s):

Laura Huppert, MDYara Abdou, MD

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Kevin Kalinsky, MD, MS
Related Content
Brittany Bychkovsky, MD, MSc, of Dana-Farber Cancer Institute
June 11th 2024

Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Lydia Pace, MD, MPH
June 5th 2024

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Ana C. Garrido-Castro, MD, a medical oncologist and codirector of the Triple-Negative Breast Cancer Working Group at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School
June 2nd 2024

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer